Lifitegrast

What is Lifitegrast?

Lifitegrast is a prescription medication used to treat the signs and symptoms of dry eye disease (DED). It is administered as an ophthalmic solution, meaning it is applied directly to the eyes in the form of eye drops. Approved by regulatory bodies for its efficacy, Lifitegrast offers a targeted approach to managing chronic dry eye, a condition characterized by insufficient tear production or poor tear quality, leading to discomfort and potential vision problems.

Marketed under the brand name Xiidra, Lifitegrast belongs to a class of drugs known as lymphocyte function-associated antigen-1 (LFA-1) antagonists. Unlike some other dry eye treatments that primarily focus on tear production or lubrication, Lifitegrast addresses one of the underlying causes of DED: inflammation on the ocular surface. By modulating specific inflammatory pathways, it aims to provide relief from the burning, stinging, and gritty sensations commonly experienced by individuals with dry eyes.

How Does it Work?

The mechanism of action of Lifitegrast is distinct and targets a key pathway involved in ocular inflammation. Lifitegrast acts as a lymphocyte function-associated antigen-1 (LFA-1) antagonist. LFA-1 is a protein found on the surface of T-cells, which are immune cells that play a crucial role in inflammatory responses. In individuals with dry eye disease, T-cells can become overactive and contribute to inflammation on the surface of the eye.

Lifitegrast works by binding to LFA-1, thereby blocking its interaction with intercellular adhesion molecule-1 (ICAM-1). ICAM-1 is expressed on the surface of various cells, including antigen-presenting cells, and is upregulated in inflammatory conditions. The LFA-1/ICAM-1 interaction is essential for T-cell activation, adhesion, and migration to inflammatory sites. By inhibiting this interaction, Lifitegrast effectively reduces T-cell activation and their subsequent migration to the ocular surface, leading to a decrease in ocular inflammation. This reduction in inflammation is crucial for alleviating the symptoms and improving the signs of dry eye disease.

Medical Uses

The primary medical use for Lifitegrast is the treatment of the signs and symptoms of chronic dry eye disease (DED), also medically known as keratoconjunctivitis sicca. DED is a common and often chronic condition that occurs when your eyes don't produce enough tears, or when the tears evaporate too quickly. This can lead to a variety of uncomfortable symptoms and, if left untreated, can potentially damage the eye's surface.

Symptoms of dry eye disease that Lifitegrast aims to alleviate include:

• A stinging, burning, or scratchy sensation in your eyes
• A feeling of something in your eyes
• Sensitivity to light
• Redness of the eyes
• Difficulty wearing contact lenses
• Blurred vision or eye fatigue
• Watery eyes (as a reflex to irritation)

Lifitegrast is prescribed when a healthcare professional determines that inflammation is contributing significantly to a patient's dry eye condition. It is not a cure for dry eye but rather a management therapy designed to provide long-term relief and improve the quality of life for individuals suffering from this persistent condition.

Dosage

The recommended dosage for Lifitegrast is one drop in each eye twice a day, approximately 12 hours apart. It is supplied in single-use containers, each designed for one-time use in both eyes. Patients should be instructed to discard the container immediately after use, even if there is solution remaining, to prevent contamination and ensure sterility.

Key instructions for administration include:

• Wash hands thoroughly before handling the single-use container.
• Twist off the cap of the single-use container.
• Tilt your head back and pull down your lower eyelid to form a pocket.
• Gently squeeze the container to instill one drop into the affected eye(s).
• Do not touch the tip of the container to your eye or any other surface to avoid contamination.
• If you are using other ophthalmic medications, wait at least 5 minutes between administering Lifitegrast and other eye drops to prevent washout.
• Remove contact lenses prior to administration and wait at least 15 minutes before reinserting them.

Consistency in dosage is important for optimal results. Patients should follow their doctor's instructions precisely and not alter the dosage without consulting their healthcare provider.

Side Effects

Like all medications, Lifitegrast can cause side effects, although not everyone experiences them. The most common side effects reported during clinical trials are generally mild to moderate and typically resolve with continued use or discontinuation of the medication. These include:

• Eye irritation or discomfort: This can manifest as a burning, stinging, or gritty sensation in the eye after instillation.
• Blurred vision: A temporary blurring of vision immediately after applying the drops.
• Dysgeusia: An unusual or altered sense of taste, often described as a metallic or chemical taste, which is thought to occur due to systemic absorption via the nasolacrimal duct.
• Eye discharge: A slight discharge from the eye.
• Headache: Some patients may experience headaches.

Less common but more serious side effects can occur, and patients should seek medical attention if they experience:

• Signs of an allergic reaction (e.g., rash, itching/swelling, severe dizziness, trouble breathing)
• Severe eye pain or persistent redness
• Changes in vision

It is important to discuss any concerns about side effects with a healthcare professional. They can provide guidance on managing common side effects or determine if a change in treatment is necessary.

Drug Interactions

Due to its topical application and minimal systemic absorption, Lifitegrast has a relatively low potential for significant drug interactions with systemic medications. The amount of Lifitegrast that enters the bloodstream after ophthalmic administration is very small, which reduces the likelihood of it interacting with drugs taken orally or by other routes.

However, when using Lifitegrast with other ophthalmic medications, it is generally recommended to observe a waiting period between applications. To prevent the washout of one medication by another, patients should typically wait at least 5 minutes between instilling Lifitegrast and any other eye drops. This ensures that each medication has sufficient time to be absorbed and exert its therapeutic effect on the eye surface.

Patients should always inform their doctor or pharmacist about all prescription, over-the-counter, and herbal products they are currently using to ensure there are no unforeseen interactions or contraindications, even if the risk is low for Lifitegrast.

FAQ

Q: How long does Lifitegrast take to work?

A: While some patients may experience initial relief within a few weeks, the full benefits of Lifitegrast, particularly in reducing inflammation and improving both signs and symptoms of dry eye, may take 6 to 12 weeks of consistent use to become fully apparent. It's important to continue using the medication as prescribed, even if immediate relief isn't felt.

Q: Can I wear contact lenses with Lifitegrast?

A: Yes, but you should remove your contact lenses prior to applying Lifitegrast eye drops. Wait at least 15 minutes after instilling the drops before reinserting your contact lenses. This is to prevent the preservative-free solution from potentially interacting with the lenses.

Q: What should I do if I miss a dose?

A: If you miss a dose, apply it as soon as you remember. However, if it's almost time for your next scheduled dose (e.g., only a few hours away), skip the missed dose and continue with your regular dosing schedule. Do not double the dose to make up for a missed one.

Q: Is Lifitegrast the same as cyclosporine?

A: No, Lifitegrast and cyclosporine (e.g., Restasis, Cequa) are different medications with distinct mechanisms of action, though both are used to treat dry eye disease. Cyclosporine is a calcineurin inhibitor, while Lifitegrast is an LFA-1 antagonist. Both work to reduce ocular inflammation, but through different pathways.

Q: How should Lifitegrast be stored?

A: Store Lifitegrast single-use containers in their original foil pouch at room temperature, between 20°C to 25°C (68°F to 77°F). Protect from light. Do not freeze. Once a foil pouch is opened, the individual containers should be used within 15 days.

Products containing Lifitegrast are available through trusted online pharmacies. You can browse Lifitegrast-based medications at ShipperVIP or Medicenter.

Summary

Lifitegrast is a significant advancement in the treatment of chronic dry eye disease, offering a targeted approach to reduce the underlying ocular inflammation that contributes to its signs and symptoms. As an LFA-1 antagonist, it works by inhibiting T-cell activation and migration, thereby alleviating discomfort and improving the health of the ocular surface. While common side effects like eye irritation and an altered sense of taste may occur, Lifitegrast is generally well-tolerated and offers a valuable option for many individuals struggling with persistent dry eyes. Always consult with a healthcare professional to determine if Lifitegrast is the right treatment option for your specific condition and to ensure proper usage and management of any potential side effects or interactions.